Erratum

After the publication of the Drug Profile by Markolf Hanefeld and Frank Schaper, Acarbose: oral antidiabetes drug with additional cardiovascular benefits, published in the February 2008 issue of Expert Review of Cardiovascular Therapy (Expert Rev. Cardiovasc. Ther. 6[2], 153–163 [2008]) it has been brought to our attention that Table 3 was written incorrectly as follows:

Table 3. Cardiovascular events in primary prevention studies of people with IGT.

	DREAM Rosiglitazone	STOP-NIDDM Acarbose	DPP Metformin
Patients	IGT/IFG (n = 5269)	IGT (n = 13,68)	IGT (n = 2155)
Reduction in diabetes incidence (*)	-60%	-34.4%	-31%
Reduction in newly diagnosed hypertension (*)	NA	-34% (p = 0.006)	+25% (p = NS)
predefined CV events (*)	+37% (p = 0.08)	- 49% (p = 0.03)	NS

*Relative risk.

DPP: Diabetes Prevention Program DREAM: Diabetes Reduction Assessment with ramipril and rosiglitazone Medication [56]; NA: Not available; NS: Not significant; STOP-NIDDM: Study TO Prevent Non-Insulin-Dependent Diabetes Mellitus [28].

The correct Table 3 is given below:

Table 3. Cardiovascular events in primary prevention studies of people with IGT.

	DREAM Rosiglitazone	STOP-NIDDM Acarbose	DPP Metformin
Patients	IGT/IFG (n = 5269)	IGT (n = 1368)	IGT (n = 2155)
Reduction in diabetes incidence (*)	-60%	-36.4%	-31%
Reduction in newly diagnosed hypertension (*)	NA	-34% (p = 0.006)	+25% (p = NS)
predefined CV events (*)	+37% (p = 0.08)	- 49% (p = 0.03)	NS

*Relative risk.

DPP: Diabetes Prevention Program DREAM: Diabetes Reduction Assessment with ramipril and rosiglitazone Medication [56]; NA: Not available; NS: Not significant; STOP-NIDDM: Study TO Prevent Non-Insulin-Dependent Diabetes Mellitus[28].

The editors of Expert Review of Cardiovascular Therapy and the authors would like to sincerely apologize for any inconvenience or confusion this may have caused the readers.